In 2008, primary kidney malignancies accounted for a predicted 4% of all cancer diagnoses in the US. There were an estimated 54,390 new diagnoses of renal cell carcinoma (RCC), which constitute approximately 90% of all malignant kidney tumors (approximately 85% clear-cell histology), and 13,010 kidney cancer deaths. 
development of cytokine therapies. IFN-α provided a small but significant benefit in response and survival in metastatic RCC, summarized in the Cochrane analysis of 6,880 patients in 58 studies. 12 An IFN-α dose of 8-18 megaunits (MU) three weekly in five studies was compared with non-immunotherapy controls. The pooled overall response rate (ORR) was 12.5 versus 1.5% for controls (pooled odds patients from six prospective trials suggested a similar benefit from first-line IFN-α, reporting a median OS of 13 months, a median time to progression (TTP) of 4.7 months, and a five-year survival rate of 10%. 13 These trials established IFN-α as a suitable control for future studies.
The minimum effective dose is 20-40MU weekly. Higher doses result in greater toxicity without higher response rates. 14 The toxicities include a flu-like syndrome of fatigue, fever, and myalgia, as well as nausea and depression. Historical attempts to combine IFN-α with other agents have not led to the development of clinically useful regimens. 15 High-dose bolus IL-2 regimens can provide durable responses in advanced RCC. Reported response rates vary from 14 to 23% 16, 17 and median duration of partial response (PR) from 11 to 19 months, 18, 19 with approximately 6% achieving durable complete radiological responses lasting up to 148 months. 19 However, this is achieved at the expense of significant toxicity, including hypotension, arrhythmias, vascular leak syndrome, and 4% treatment-related mortality. 18 Efforts to combine IL-2 with other therapies including IFN-α and fluorouracil in order to reduce toxicity have not been successful. A pooled analysis of these regimens compared with non-IL-2-containing controls has confirmed that they convey higher toxicity yet no significant OS benefit. 20 Despite the 5-7% durable complete response (CR) rate of high-dose IL-2, excess toxicity restricts its use to patients of good performance status and limits its availability. One retrospective study has reported that high expression levels of carbonic anhydrase IX (CAIX) correlate with the response rate. 21 Currently, the high dose IL-2 SELECT trial is recruiting to validate the predictive value of CAIX in a prospective setting.
Targeted Agents
The von Hippel Lindau (VHL) gene is a tumor-suppressor gene found to have mutated in 70-80% of sporadic clear-cell RCC. In normal oxygen tensions, wild-type VHL gene product binds and degrades hypoxiainducible factors (HIFs) 1α and 2α. In hypoxic conditions or absent VHL gene product, HIF-1α accumulates and leads to the production of various growth factors, including transforming growth factor-α (TGF-α), platelet-derived growth factor (PDGF), and vascular endothelial growth factor (VEGF). Investigators have focused on targeting this pathway, which is important for cellular proliferation and angiogenesis in RCC.
Bevacizumab
Bevacizumab is a humanized monoclonal antibody directed against the VEGF receptor (VEGFR). Its activity was first demonstrated in metastatic RCC in a phase II study that reported a TTP (primary end-point)
advantage for bevacizumab at 10mg/kg every two weeks over placebo of 4.8 versus 2.5 months (p<0.001). 22 Bevacizumab was well-tolerated, with asymptomatic proteinuria and hypertension being the most frequently detected toxicities. The double-blind randomized AVOREN phase III trial compared the combination of IFN-α (9MU three times weekly) plus bevacizumab with IFN-α plus placebo (see Table 1 ). 23 
CALGB = Cancer and Leukemia Group B; IFN = interferon; HR = hazard ratio; CI = confidence interval; VEGF = vascular endothelial growth factor.
improved with the addition of bevacizumab to IFN-α (10.2 versus 5.4 months; p=0.0001), and this pre-specified analysis was accepted for regulatory submission. The PFS benefit was seen in all risk groups, and was independent of the IFN-α dose. The Cancer and Leukemia Group B (CALGB) 90206 phase III study randomized between IFN-α plus bevacizumab and IFN-α alone and reported a similar PFS benefit (8.5 versus 5.2 months; p<0.0001) and a significant improvement in ORR (25.5 versus 13.1%; p<0.0001) (see Table 1 ). 24 Toxicities of the combination in both phase III studies were manageable: grade 3 hypertension, anemia, fatigue, and proteinuria, occurring more frequently in the combination arm. The evidence for this combination is persuasive; however, its use has been limited by the simultaneous availability of effective oral therapies.
Sunitinib
Sunitinib malate is an oral oxinodole tyrosine kinase inhibitor (TKI) of the VEGF2, PDGF, c-KIT, and FLT-3 receptors. 25 It is orally administered at a dose of 50mg once daily for four of every six weeks. 26 Phase II studies reported response rates of 40-43%, with an additional 22-27%
having stable disease (SD) for more than three months. 27, 28 Median TTP was 8.7 months (95% CI 5.5-10.7 months) 27 and median PFS 8.3
months (95% CI 7.8-14.5 months). 28 The most frequently observed toxicities were fatigue and diarrhea.
A total of 750 clear-cell RCC patients were recruited into a randomized multicentre phase III trial comparing first-line sunitinib with IFN-α (see Table 1 ). 29 The primary end-point was PFS with secondary end-points including OS and ORR. were the most frequent side effects.
A phase III study recruited 626 systemic therapy-naïve patients with poor-risk features (see Table 1 ). 38 Patients were randomized to one of three groups: IFN-α 9-18MU three times weekly alone, temsirolimus metastatic RCC patients given 10mg daily continuous dosing. 39 The PR rate was 32% and a further 51% had SD for greater than three months.
Kidney Cancer
A phase III study of everolimus versus best supportive care (BSC) recruited 410 patients who had progressed following VEGFR TKI therapy (sunitinib or sorafenib) and many of whom had received other additional lines of treatment (see Table 1 ). 40 The primary end-point was PFS, which favored everolimus (4 versus 1.9 months; p<0.0001).
It was well-tolerated, with stomatitis, anemia, and rash the most commonly reported toxicities. Everolimus is currently the only treatment showing benefit in a randomized phase III setting following progression on VEGFR TKI therapy.
Other Promising Agents
A number of other agents show clinical efficacy in advanced RCC.
Phase II activity has been reported for the anti-VEGFR therapies axitinib, 41 pazopanib, 42 and cediranib, 43 with VEGF-Trap and IMC-1121B also currently undergoing a clinical trial investigation. Other small molecules investigated in a mixture of phase II/III randomized and non-randomized studies include the epidermal growth factor receptor (EGFR) inhibitor erolitinib, 44 the EGFR/Her2 inhibitor lapatinib, 45 the proteasome inhibitor bortezomib, 46 and the anti-TNF-α antibody infliximab. 47 Although some have shown activity, other agents remain to demonstrate clinical benefits. A final analysis of the phase III study of lapatinib versus hormonal treatment suggested equivalent efficacy in cytokine-refractory disease, but the choice of control in this study remains debatable for the general clinic population. 48 This rapid expansion in novel agents holds great promise, but also presents a considerable challenge in identifying the most effective agents, combinations, and sequences.
Metastatic Non-clear-cell Renal Cell Carcinoma
Non-clear-cell RCC accounts for 15% of RCCs and comprises predominantly papillary and chromophobe tumors. In particular, metastatic papillary-cell RCC often responds poorly to therapy and carries a poorer prognosis than clear-cell RCC. Non-clear-cell RCC patients were excluded from many of the main registration studies.
Trials have reported activity of sorafenib, sunitinib, and temsirolimus in metastatic papillary tumors and of sorafenib and sunitinib in chromophobe tumors. 33, [49] [50] [51] [52] Therefore, it is reasonable to consider using these agents for metastatic non-clear-cell RCC. Inhibition of c-MET has also proved promising in papillary cell carcinoma, and is currently being further evaluated. 
Scheduling-A Sequential or Combination Approach?
Multidrug schedules aim to overcome resistance and optimize patient outcomes. It is currently unclear whether sequences or combinations of active agents are preferable for the optimal management of advanced RCC. A retrospective analysis of 29 patients who received sorafenib followed by sunitinib and 20 patients who received the reverse sequence has been published. 54 Responses were seen in both groups and a non-significant trend toward benefit assessed by median duration of SD and median OS was seen for those who received sorafenib first. A number of other reports validate the potential efficacy of this sequential approach. Responses have also been reported for sunitinib following bevacizumab, 55 sorafenib following bevacizumab, 56 and sorafenib following bevacizumab or sunitinib. 57 Similarly, sunitinib, sorafenib, and axitinib have been reported to have second-line clinical benefit in patients who have received a variety of prior antiangiogenic therapies. 41, 58 Combination regimens aim to maximize response and overcome or avoid resistance, yet maintain an acceptable toxicity profile. or sunitinib for poor-risk patients (see Table 2 ). Data for both sunitinib and Second-line therapy recommendations depend on previous treatment exposure (see Table 2 
